Abstract: The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
December 26, 2017
Assignee:
Acenda Pharma, Inc.
Inventors:
Haiyung Cheng, Chi-Feng Lin, Jhen-Hua Shih, Alexander C. H. Wu
Abstract: The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.
Type:
Grant
Filed:
October 17, 2016
Date of Patent:
July 4, 2017
Assignee:
Acenda Pharma, Inc.
Inventors:
Haiyung Cheng, Chi-Feng Lin, Jhen-Hua Shih, Alexander C. H. Wu
Abstract: The present invention relates to a method and an improved composition for improving the absorption of an ester prodrug in a subject. The method includes co-administering to the subject an effective amount of the ester prodrug or a pharmaceutical acceptable salt thereof, and a sufficient amount of adjuvant to impede a carboxylesterase-mediated hydrolysis of the ester prodrug in vivo, wherein the adjuvant is selected from the gnzup consisting of triacetin, triethyl citrate and a combination of both. The present invention also relates to a method for impeding carboxylesterase-mediated hydrolysis of esters, including ester prodrugs.